MBM ScienceBridge GmbH Negotiates License Agreement Between the Georg-August-University Gottingen, Universitatsmedizin, the University of Regensburg, and the UK’s Medical Research Council Technology for a New Therapy of Inflammatory and Immune Diseases
Reference MRCT: MRCT120110
Georg-August-University Gottingen, University of Regensburg and MRC
Technology (MRCT) have signed exclusive license agreements through MBM
ScienceBridge GmbH and in agreement with Bayerische Patentallianz GmbH, for
the development of a novel therapy of inflammatory and immune diseases based
on the depletion of inflammatory monocytes. The first targets will be
rheumatoid arthritis (RA) and multiple sclerosis (MS).
MBM ScienceBridge GmbH, the technology transfer organization of the
Georg-August-Universitat Gottingen, successfully negotiated a license
agreement between the University of Gottingen, the University of Regensburg
and the Medical Research Council Technology (MRCT). Scientists at the
Universities of Regensburg and of Gottingen around Prof. Dr.
Dr.
therapeutic approach to the treatment of RA and MS based on a panel of unique
antibodies.
The collaboration between these academic technology transfer offices will
enable MBM ScienceBridge GmbH to access the world-class antibody humanization
expertise of MRCT’s Centre for Therapeutics Discovery and the work of its
Therapeutic Antibody Group, led by Dr
demonstrates MRCT’s world-leading capability to take lab tool compounds and
turn them into clinical candidates, which will then be licensed to the
Pharmaceutical and biotech industry.
Dr
example of the innovative ways that MRCT is now exploiting both its antibody
humanization and drug discovery capabilities. We can collaborate with other
technology transfer organizations, on a shared risk basis, to develop novel
antibodies and targets with therapeutic potential. When the resulting
clinical candidate is subsequently licensed, an activity MRCT has proven
itself very successful in achieving, both parties will not only accomplish
their translational research aims, but also share in its commercial success
going forward.”
MRCT receives an exclusive Worldwide license to the related IP rights of
the Universities. MRCT as well as both Universities through the MBM
ScienceBridge GmbH will then receive downstream payments dependent on
successful development and out-licensing of the antibody. This income will be
used for further research within the organisations.
Notes to Editors
About Rheumatoid Arthritis and Multiple Sclerosis
The prevalence of rheumatoid arthritis ranges from 0.24 % to 1.0 % among
the populations of the seven major markets of
varies widely by geographic region. Among the major markets, it ranges from a
high of approximately 170 per 100,000 in the UK to a low of approximately 2.5
per 100,000 in
to an estimated
system therapy areas.
About MBM ScienceBridge GmbH
The MBM ScienceBridge GmbH is a fully owned subsidiary of the University
of Gottingen and acts on its behalf as a technology transfer interface to
companies around the world. The IP portfolio managed by MBM ScienceBridge
covers innovation in the areas of Life Sciences, Chemistry, Physics,
Agriculture and Medical Technologies.
The Georg-August-Universitat Gottingen, Universitatsmedizin,
founded in 1737 and in the spirit of the enlightenment, has laid the
foundation – both in the natural sciences and humanities, for the present day
University’s excellent reputation.
About Bayerische Patentallianz GmbH
Bayerische Patentallianz GmbH assesses and markets the inventions of more
than 16,000 researchers in the German Federal State of Bavaria. With its
interdisciplinary team composed of scientists and economic experts it attends
to universities and universities of applied sciences in Bavaria when it comes
to subjects concerning inventions, patents and licenses. Bayerische
Patentallianz GmbH is a company owned by Universitat Bayern e.V. and
Hochschule Bayern e.V.
About Medical Research Council Technology (MRCT)
MRCT is the exclusive commercialisation agent for the UK Medical Research
Council, working to translate cutting edge scientific discoveries into
commercial products. MRCT bridges the gap between innovative basic science
and making medicine. MRCT works to provide drug-like candidate molecules to
innovative new drug targets, and to translate innovative antibody-dased drug
targets into potent and selective therapeutic antibody canditates giving
pharmaceutical and biotechnology companies new starting points for drug
discovery and development, based on MRC advances in science. MRCT’s
Therapeutic Antibody Group scientists have a proven track record of success
in antibody humanization which extends over 20 years and has produced 10
clinical candidates and two regulatory approved humanized antibodies:
Elan/Biogen Idec’s Tysabri(R) and Chugai/Roche’s Actemra(R).
http://www.mrctechnology.org
SOURCE Medical Research Council Technology (MRCT)